Nuclear Factor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Thioredoxin Trx-1 Regulates the Major Oxidative Stress Response Transcription Factor, Skn-1, in Caenorhabditis Elegans
The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2016 THE THIOREDOXIN TRX-1 REGULATES THE MAJOR OXIDATIVE STRESS RESPONSE TRANSCRIPTION FACTOR, SKN-1, IN CAENORHABDITIS ELEGANS Katie C. McCallum Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Cellular and Molecular Physiology Commons, Medicine and Health Sciences Commons, Molecular Genetics Commons, and the Organismal Biological Physiology Commons Recommended Citation McCallum, Katie C., "THE THIOREDOXIN TRX-1 REGULATES THE MAJOR OXIDATIVE STRESS RESPONSE TRANSCRIPTION FACTOR, SKN-1, IN CAENORHABDITIS ELEGANS" (2016). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 655. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/655 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. THE THIOREDOXIN TRX-1 REGULATES THE MAJOR OXIDATIVE STRESS RESPONSE TRANSCRIPTION FACTOR, SKN-1, IN CAENORHABDITIS ELEGANS A DISSERTATION Presented to the Faculty of The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center Graduate School of Biomedical Sciences in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY by Katie Carol McCallum, B.S. -
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. -
The Autophagy Receptor SQSTM1/P62 Mediates Anti-Inflammatory Actions of the Selective NR3C1/ Glucocorticoid Receptor Modulator Compound a (Cpda) in Macrophages
Autophagy ISSN: 1554-8627 (Print) 1554-8635 (Online) Journal homepage: http://www.tandfonline.com/loi/kaup20 The autophagy receptor SQSTM1/p62 mediates anti-inflammatory actions of the selective NR3C1/ glucocorticoid receptor modulator compound A (CpdA) in macrophages Viacheslav Mylka, Julie Deckers, Dariusz Ratman, Lode De Cauwer, Jonathan Thommis, Riet De Rycke, Francis Impens, Claude Libert, Jan Tavernier, Wim Vanden Berghe, Kris Gevaert & Karolien De Bosscher To cite this article: Viacheslav Mylka, Julie Deckers, Dariusz Ratman, Lode De Cauwer, Jonathan Thommis, Riet De Rycke, Francis Impens, Claude Libert, Jan Tavernier, Wim Vanden Berghe, Kris Gevaert & Karolien De Bosscher (2018) The autophagy receptor SQSTM1/p62 mediates anti- inflammatory actions of the selective NR3C1/glucocorticoid receptor modulator compound A (CpdA) in macrophages, Autophagy, 14:12, 2049-2064, DOI: 10.1080/15548627.2018.1495681 To link to this article: https://doi.org/10.1080/15548627.2018.1495681 © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Published online: 14 Sep 2018. Submit your article to this journal Article views: 907 View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=kaup20 AUTOPHAGY 2018, VOL. 14, NO. 12, 2049–2064 https://doi.org/10.1080/15548627.2018.1495681 RESEARCH PAPER - BASIC SCIENCE The autophagy receptor SQSTM1/p62 mediates anti-inflammatory actions of the selective NR3C1/glucocorticoid receptor modulator -
The Human Dcn1-Like Protein DCNL3 Promotes Cul3 Neddylation at Membranes
The human Dcn1-like protein DCNL3 promotes Cul3 neddylation at membranes Nathalie Meyer-Schallera, Yang-Chieh Choub,c, Izabela Sumaraa, Dale D. O. Martind, Thimo Kurza, Nadja Kathedera, Kay Hofmanne, Luc G. Berthiaumed, Frank Sicherib,c, and Matthias Petera,1 aInstitute of Biochemistry, Eidgeno¨ssiche Technische Hochschule, 8093 Zurich, Switzerland; bCenter for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, ON, Canada M5G 1X5; cDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada M5S 1A8; dDepartment of Cell Biology, University of Alberta, Edmonton, AB, Canada T6G 2H7; and eBioinformatics Group, Miltenyi Biotec, 51429 Bergisch-Gladbach, Germany Edited by Michael Rape, University of California, Berkeley, CA, and accepted by the Editorial Board June 9, 2009 (received for review December 9, 2008) Cullin (Cul)-based E3 ubiquitin ligases are activated through the enzyme and promotes Nedd8 conjugation through formation of attachment of Nedd8 to the Cul protein. In yeast, Dcn1 (defective this complex (14, 15). Human cells harbor 5 Dcn1-like proteins in Cul neddylation 1 protein) functions as a scaffold-like Nedd8 termed DCNL1–DCNL5 (also named DCUN1D 1–5 for defec- E3-ligase by interacting with its Cul substrates and the Nedd8 E2 tive in Cul neddylation 1 domain-containing protein 1–5) (Fig. Ubc12. Human cells express 5 Dcn1-like (DCNL) proteins each S1). These DCNLs have distinct amino-terminal domains, but containing a C-terminal potentiating neddylation domain but dis- share a conserved C-terminal potentiating neddylation (PONY) tinct amino-terminal extensions. Although the UBA-containing domain, which in yeast Dcn1 is necessary and sufficient for Cul DCNL1 and DCNL2 are likely functional homologues of yeast Dcn1, neddylation in vivo and in vitro (14). -
Domain Structure of the Glucocorticoid Receptor Protein
Proc. Nati. Acad. Sci. USA Vol. 84, pp. 4437-4440, July 1987 Biochemistry Domain structure of the glucocorticoid receptor protein (proteolysis/steroid binding/DNA binding/protein sequence) JAN CARLSTEDT-DUKE*, PER-ERIK STROMSTEDT*, ORJAN WRANGEt, TOMAS BERGMANt, JAN-AKE GuSTAFSSON*, AND HANS JORNVALLf *Department of Medical Nutrition, Karolinska Institute, Huddinge University Hospital, F69, S-141 86 Huddinge, Sweden; and Departments of tMedical Cell Genetics and tChemistry, Karolinska Institute, Box 60400, S-104 01 Stockholm, Sweden Communicated by Viktor Mutt, March 26, 1987 (receivedfor review December 1, 1986) ABSTRACT The purified rat liver glucocorticoid receptor GR was eluted with 27.5 mM MgCl2 and further purified by protein was analyzed by limited proteolysis and amino acid chromatography on DEAE-Sepharose, eluted with a linear sequence determination. The NH2 terminus appears to be NaCl gradient. The receptor was detected by analysis for 3H blocked. The steroid-binding domain, defined by a unique radioactivity. Each purification resulted in a yield of '50 ,g tryptic cleavage site, corresponds to the COOH-terminal part of GR, starting from eight rat livers. The purified prepara- of the protein with the domain border in the region of residue tions of GR contained the 94-kDa GR, the 72-kDa GR- 518. The DNA-binding domain, defined by a region with associated protein that is unrelated to GR (12, 13), as well as chymotryptic cleavage sites, is immediately adjacent to the very small amounts of proteolytic GR fragments (usually steroid-binding domain and reflects another domain border in <5% of total protein according to densitometric analysis of the region of residues 410-414. -
Mtor: a Pharmacologic Target for Autophagy Regulation
mTOR: a pharmacologic target for autophagy regulation Young Chul Kim, Kun-Liang Guan J Clin Invest. 2015;125(1):25-32. https://doi.org/10.1172/JCI73939. Review mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregulated in many human diseases. mTOR also plays a crucial role in regulating autophagy. This Review provides an overview of the mTOR signaling pathway, the mechanisms of mTOR in autophagy regulation, and the clinical implications of mTOR inhibitors in disease treatment. Find the latest version: https://jci.me/73939/pdf The Journal of Clinical Investigation REVIEW SERIES: AUTOPHAGY Series Editor: Guido Kroemer mTOR: a pharmacologic target for autophagy regulation Young Chul Kim and Kun-Liang Guan Department of Pharmacology and Moores Cancer Center, UCSD, La Jolla, California, USA. mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregulated in many human diseases. mTOR also plays a crucial role in regulating autophagy. This Review provides an overview of the mTOR signaling pathway, the mechanisms of mTOR in autophagy regulation, and the clinical implications of mTOR inhibitors in disease treatment. Overview of mTOR signaling pathway such as insulin and IGF activate their cognate receptors (recep- Nutrients, growth factors, and cellular energy levels are key deter- tor tyrosine kinases [RTKs]) and subsequently activate the PI3K/ minants of cell growth and proliferation. mTOR, a serine/threon- AKT signaling axis. -
Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook
International Journal of Molecular Sciences Review Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook Naila Qayyum 1,†, Muhammad Haseeb 1,† , Moon Suk Kim 1 and Sangdun Choi 1,2,* 1 Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea; [email protected] (N.Q.); [email protected] (M.H.); [email protected] (M.S.K.) 2 S&K Therapeutics, Woncheon Hall 135, Ajou University, Suwon 16499, Korea * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Thioredoxin-interacting protein (TXNIP), widely known as thioredoxin-binding protein 2 (TBP2), is a major binding mediator in the thioredoxin (TXN) antioxidant system, which involves a reduction-oxidation (redox) signaling complex and is pivotal for the pathophysiology of some diseases. TXNIP increases reactive oxygen species production and oxidative stress and thereby contributes to apoptosis. Recent studies indicate an evolving role of TXNIP in the pathogenesis of complex diseases such as metabolic disorders, neurological disorders, and inflammatory illnesses. In addition, TXNIP has gained significant attention due to its wide range of functions in energy metabolism, insulin sensitivity, improved insulin secretion, and also in the regulation of glucose and tumor suppressor activities in various cancers. This review aims to highlight the roles of TXNIP in the field of diabetology, neurodegenerative diseases, and inflammation. TXNIP is found to be a promising novel therapeutic target in the current review, not only in the aforementioned diseases but also in prolonged microvascular and macrovascular diseases. Therefore, TXNIP inhibitors hold promise for preventing the growing incidence of complications in relevant diseases. -
Genome-Scale Identification of Transcription Factors That Mediate An
ARTICLE DOI: 10.1038/s41467-018-04406-2 OPEN Genome-scale identification of transcription factors that mediate an inflammatory network during breast cellular transformation Zhe Ji 1,2,4, Lizhi He1, Asaf Rotem1,2,5, Andreas Janzer1,6, Christine S. Cheng2,7, Aviv Regev2,3 & Kevin Struhl 1 Transient activation of Src oncoprotein in non-transformed, breast epithelial cells can initiate an epigenetic switch to the stably transformed state via a positive feedback loop that involves 1234567890():,; the inflammatory transcription factors STAT3 and NF-κB. Here, we develop an experimental and computational pipeline that includes 1) a Bayesian network model (AccessTF) that accurately predicts protein-bound DNA sequence motifs based on chromatin accessibility, and 2) a scoring system (TFScore) that rank-orders transcription factors as candidates for being important for a biological process. Genetic experiments validate TFScore and suggest that more than 40 transcription factors contribute to the oncogenic state in this model. Interestingly, individual depletion of several of these factors results in similar transcriptional profiles, indicating that a complex and interconnected transcriptional network promotes a stable oncogenic state. The combined experimental and computational pipeline represents a general approach to comprehensively identify transcriptional regulators important for a biological process. 1 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. 2 Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. 3 Department of Biology, Howard Hughes Medical Institute and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 20140, USA. 4Present address: Department of Pharmacology and Biomedical Engineering, Northwestern University, Evanston 60611 IL, USA. -
SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
ORIGINAL CONTRIBUTION SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis Faisal Fecto, MD; Jianhua Yan, MD, PhD; S. Pavan Vemula; Erdong Liu, MD; Yi Yang, MS; Wenjie Chen, MD; Jian Guo Zheng, MD; Yong Shi, MD, PhD; Nailah Siddique, RN, MSN; Hasan Arrat, MD; Sandra Donkervoort, MS; Senda Ajroud-Driss, MD; Robert L. Sufit, MD; Scott L. Heller, MD; Han-Xiang Deng, MD, PhD; Teepu Siddique, MD Background: The SQSTM1 gene encodes p62, a major In silico analysis of variants was performed to predict al- pathologic protein involved in neurodegeneration. terations in p62 structure and function. Objective: To examine whether SQSTM1 mutations con- Results: We identified 10 novel SQSTM1 mutations (9 tribute to familial and sporadic amyotrophic lateral scle- heterozygous missense and 1 deletion) in 15 patients (6 rosis (ALS). with familial ALS and 9 with sporadic ALS). Predictive in silico analysis classified 8 of 9 missense variants as Design: Case-control study. pathogenic. Setting: Academic research. Conclusions: Using candidate gene identification based on prior biological knowledge and the functional pre- Patients: A cohort of 546 patients with familial diction of rare variants, we identified several novel (n=340) or sporadic (n=206) ALS seen at a major aca- SQSTM1 mutations in patients with ALS. Our findings demic referral center were screened for SQSTM1 muta- provide evidence of a direct genetic role for p62 in ALS tions. pathogenesis and suggest that regulation of protein deg- radation pathways may represent an important thera- Main Outcome Measures: We evaluated the distri- peutic target in motor neuron degeneration. bution of missense, deletion, silent, and intronic vari- ants in SQSTM1 among our cohort of patients with ALS. -
And CAND1-Dependent Remodelling of the Budding Yeast SCF Complex
ARTICLE Received 31 Jan 2013 | Accepted 20 Feb 2013 | Published 27 Mar 2013 DOI: 10.1038/ncomms2628 OPEN CSN- and CAND1-dependent remodelling of the budding yeast SCF complex Aleksandra Zemla1, Yann Thomas1, Sylwia Kedziora1, Axel Knebel1, Nicola T Wood1, Gwenae¨l Rabut2 & Thimo Kurz1 Cullin–RING ligases (CRLs) are ubiquitin E3 enzymes with variable substrate-adaptor and -receptor subunits. All CRLs are activated by modification of the cullin subunit with the ubiquitin-like protein Nedd8 (neddylation). The protein CAND1 (Cullin-associated-Nedd8- dissociated-1) also promotes CRL activity, even though it only interacts with inactive ligase complexes. The molecular mechanism underlying this behaviour remains largely unclear. Here, we find that yeast SCF (Skp1–Cdc53–F-box) Cullin–RING complexes are remodelled in a CAND1-dependent manner, when cells are switched from growth in fermentable to non-fermentable carbon sources. Mechanistically, CAND1 promotes substrate adaptor release following SCF deneddylation by the COP9 signalosome (CSN). CSN- or CAND1- mutant cells fail to release substrate adaptors. This delays the formation of new complexes during SCF reactivation and results in substrate degradation defects. Our results shed light on how CAND1 regulates CRL activity and demonstrate that the cullin neddylation– deneddylation cycle is not only required to activate CRLs, but also to regulate substrate specificity through dynamic substrate adaptor exchange. 1 Scottish Institute for Cell Signalling, Protein Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, UK. 2 CNRS, Universite´ Rennes 1, Institut de Ge´ne´tique et De´veloppement de Rennes, 2 avenue du Professeur Le´on Bernard, CS 34317, Rennes Cedex 35043, France. -
NF-B in Hematological Malignancies
biomedicines Review NF-κB in Hematological Malignancies Véronique Imbert * and Jean-François Peyron Centre Méditerranéen de Médecine Moléculaire, INSERM U1065, Université Côte d’Azur, 06204 Nice, France; [email protected] * Correspondence: [email protected]; Tel.: +33-489-064-315 Academic Editor: Véronique Baud Received: 28 April 2017; Accepted: 26 May 2017; Published: 31 May 2017 Abstract: NF-κB (Nuclear Factor K-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to many diseases, including cancer, diabetes, chronic inflammation, and autoimmunity. In the present review, we focus our attention on the mechanisms of NF-κB deregulation in hematological malignancies. Key positive regulators of NF-κB signaling can act as oncogenes that are often prone to chromosomal translocation, amplifications, or activating mutations. Negative regulators of NF-κB have tumor suppressor functions, and are frequently inactivated either by genomic deletions or point mutations. NF-κB activation in tumoral cells is also driven by the microenvironment or chronic signaling that does not rely on genetic alterations. Keywords: NF-κB; leukemia; lymphoma 1. Introduction The NF-κB family of transcription factors coordinates inflammatory responses, innate and adaptive immunity, cellular differentiation, proliferation, and survival in all multicellular organisms. The NF-κB system is tightly controlled at various levels, and deregulations of NF-κB homeostasis have been implicated in a wide range of diseases, ranging from inflammatory and immune disorders to cancer [1,2]. In particular, NF-κB is a key link between chronic inflammation and cancer transformation [3]. -
Is Glyceraldehyde-3-Phosphate Dehydrogenase a Central Redox Mediator?
1 Is glyceraldehyde-3-phosphate dehydrogenase a central redox mediator? 2 Grace Russell, David Veal, John T. Hancock* 3 Department of Applied Sciences, University of the West of England, Bristol, 4 UK. 5 *Correspondence: 6 Prof. John T. Hancock 7 Faculty of Health and Applied Sciences, 8 University of the West of England, Bristol, BS16 1QY, UK. 9 [email protected] 10 11 SHORT TITLE | Redox and GAPDH 12 13 ABSTRACT 14 D-Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an immensely important 15 enzyme carrying out a vital step in glycolysis and is found in all living organisms. 16 Although there are several isoforms identified in many species, it is now recognized 17 that cytosolic GAPDH has numerous moonlighting roles and is found in a variety of 18 intracellular locations, but also is associated with external membranes and the 19 extracellular environment. The switch of GAPDH function, from what would be 20 considered as its main metabolic role, to its alternate activities, is often under the 21 influence of redox active compounds. Reactive oxygen species (ROS), such as 22 hydrogen peroxide, along with reactive nitrogen species (RNS), such as nitric oxide, 23 are produced by a variety of mechanisms in cells, including from metabolic 24 processes, with their accumulation in cells being dramatically increased under stress 25 conditions. Overall, such reactive compounds contribute to the redox signaling of the 26 cell. Commonly redox signaling leads to post-translational modification of proteins, 27 often on the thiol groups of cysteine residues. In GAPDH the active site cysteine can 28 be modified in a variety of ways, but of pertinence, can be altered by both ROS and 29 RNS, as well as hydrogen sulfide and glutathione.